...NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track designation to DP-VPA...
...not provide a timeline. Jiangsu NHWA has exclusive rights from D-Pharm to develop and commercialize DP-VPA...
...D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Jiangsu NHWA Pharmaceutical Co. Ltd. (SZSE:002262), Xuzhou, China Product: DP-VPA...

...plasminogen activator inhibitor-1 (PAI-1) in Phase II testing to treat acute ischemic stroke; and D-Pharm's DP-VPA...

...plasminogen activator inhibitor-1 (PAI-1) in Phase II testing to treat acute ischemic stroke; and D-Pharm's DP-VPA...

...NHWA under a 2011 deal that granted Jiangsu NHWA exclusive rights to develop and commercialize DP-VPA...

...membrane-activated lipophilic chelator of zinc, copper and calcium ions. D-Pharm's next most advanced product is DP-VPA...

...membrane-activated lipophilic chelator of zinc, copper and calcium ions. D-Pharm's next most advanced product is DP-VPA...

...D-Pharm granted NHWA exclusive rights to develop and commercialize DP-VPA in China for epilepsy. D-Pharm will...

...steps could include evaluating the safety and efficacy of the analog in additional animal models. DP-VPA...

...Next steps include testing HDAC inhibitors in models of neuronal injury or neurodegeneration. D-Pharm Ltd.'s DP-VPA...

...and the company hopes to partner the compound in late 2006. Behind DP-b99, the company's DP-VPA...